Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of notoginsenoside Ft1

A technology of notoginseng saponins and uses, applied in the field of medicine, can solve problems such as recurrent attacks, achieve the effect of improving weight loss and good application prospects

Inactive Publication Date: 2015-07-15
SHANGHAI UNIV OF T C M
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, sulfasalazine, 5-aminosalicylic acid (5-ASA) sustained-release dosage forms, and corticosteroids are still the main drugs for clinical treatment of ulcers, and patients often need long-term medication maintenance, often recurrent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of notoginsenoside Ft1
  • Use of notoginsenoside Ft1
  • Use of notoginsenoside Ft1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] 1. Experimental materials

[0043] 1.1 Medicinal materials

[0044] Notoginseng saponin Ft1 (HPLC purity ≥98%, Chengdu Master Biotechnology Co., Ltd.); Dextran sodium sulfate (DSS, CAS: 9011-18-1, MW36-50kDa, produced by MP Biomedicals, USA); Willow Azasulfapyridine (SASP, CAS: 599-79-1, molecular weight 398.39, HPLC purity ≥ 98%, produced by Sigma-Aldrich, USA).

[0045] 1.2 Experimental animals

[0046] C57BL / 6 female mice (8 weeks) weighing 20±2 g were provided by the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine, animal qualification certificate number: SYXK (Shanghai) 2009-0069. Placed in a conventional feeding environment, free access to food and water.

[0047] 2. Experimental method

[0048] 2.1 Establishment of ulcerative colitis model

[0049] C57BL / 6 female mice (20±2g) with uniform body weight were selected, and the internationally accepted method for modeling ulcerative colitis (Gastroenterology2002, 123:256-70; PLoS...

Embodiment 2

[0073] The preparation of embodiment 2 tablet

[0074] Utilize conventional technique, mix following component, then directly compress tablet, prepare the pharmaceutical composition of tablet form, its formula is as follows:

[0075]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, and especially relates to a use of notoginsenoside Ft1. The invention discloses the use of notoginsenoside Ft1, prodrugs and pharmaceutical salts or plant extracts containing notoginsenoside Ft1 in preparation of drugs or health-care products for prevention or treatment of ulcerative colitis. The notoginsenoside Ft1 disclosed for the first time can significantly improve the experimental ulcerative colitis mice weight reduction, bloody stool, shortening of colon, tissue pathological damage and other symptoms, provides a new choice for clinical treatment of ulcerative colitis, and has a good application prospect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the use of notoginseng saponin Ft1. Background technique [0002] Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the colon and rectum with unknown etiology. The main symptoms are diarrhea, mucus pus and blood, abdominal pain and tenesmus. Ulcer formation is a common and intractable disease of the digestive tract with pathological characteristics. In severe cases, there may be extraintestinal symptoms such as fever, arthritis, iritis, erythema nodosum, and serious complications such as colon bleeding, perforation, and cancer. The acute fulminant type of this disease has a high mortality rate, and the chronic persistent type is prone to canceration. It is reported that the incidence rate is 5-20 times higher than that of normal people, with an average of 3.5%-7%. The canceration rate of patients is 20% at 10 years, and 40% at 25 years or more, especiall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P1/04A23L1/30A61K36/258A61K36/25
Inventor 窦薇王峥涛张晶晶丁丽丽孙阿宁张二云
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com